(NASDAQ: ORIC) Oric Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.65%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 7.68%.
Oric Pharmaceuticals's revenue in 2023 is $0.On average, 2 Wall Street analysts forecast ORIC's revenue for 2026 to be $1,085,570,671, with the lowest ORIC revenue forecast at $86,191,038, and the highest ORIC revenue forecast at $2,084,950,304. On average, 2 Wall Street analysts forecast ORIC's revenue for 2027 to be $4,506,209,310, with the lowest ORIC revenue forecast at $20,729,490, and the highest ORIC revenue forecast at $8,991,689,131.
In 2028, ORIC is forecast to generate $23,822,002,830 in revenue, with the lowest revenue forecast at $23,822,002,830 and the highest revenue forecast at $23,822,002,830.